A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC Patients
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Japan Oncology Network in Hepatobiliary and Pancreas (JON-HBP).
Phase
—
Status
Completed
Study type
Observational
Enrollment
729actual
Sites
22
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-22 | actual | When the study began enrolling |
| Primary completion | 2026-02-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-28 | actual | The whole study's end, after follow-up |
| First posted | 2025-08-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Biliary Tract Cancer
Primary outcome
what the primary-completion date above is the date OFTime to treatment failure (TTF)
measured From 1st dose of first-line systemic therapy until disease progression or death by any cause or discontinuation of first-line systemic therapy for unresectable BTC by physician's decision, whichever came first, assessed up to 2 years.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed